COVID-19’s lactoferrin boost: Jatenergy hit record sales and plans to make anti-viral supplement
Australian-listed Jatenergy has revealed record-breaking sales as demand for its lactoferrin dairy products surged in China.
The firm hit a record monthly revenue of AUD$8.5m (US$5.4m) in February and AUD$8.1m (US$5.2m) in March, it said in its Q1 financial report.
Taking the limelight is its Neurio lactoferrin milk powder offerings, which cater to infants, middle-aged adults and the elderly.
At its peak in February, the product range brought in sales of AUD$5.2m (US$3.3m), almost a five-fold jump from last February’s AUD$1.09m (US$702k).
